Welwyn Garden City (7th September 2010) – Cresset today announced that it has expanded its computational chemistry software sales team in the U.S. and Europe. As a result of this growth, the company looks forward to significantly increasing its presence in the European and U.S. markets in 2011.
Dr Mike Breen joins Cresset from ThomsonReuters (LifeSciences) where he headed the EMEA regional sales team. Although he began his career in the lab at Smith & Nephew and Servier, Mike has since gained extensive experience in developing effective high level sales teams for a number of major life sciences software and information publishers. Mike will head up the European Sales team and will be responsible for developing Cresset’s global sales strategy.
Dr Rae Lawrence joins Cresset from ACD/Labs where she managed accounts for the Northern California and Pacific Northwest territories. She has a strong background in computational chemistry tools having also previously worked at Chemical Computing Group, where she was involved with the development of bioisostere replacement tools within MOE. Rae will act as North American territory manager.
“Mike and Rae have a wealth of sales experience, as well as backgrounds in computational biology and chemistry, and an intimate knowledge of their territories. They are ideally placed to help us cement our success in the European and North American markets,” said Rob Scoffin, Chief Executive Officer of Cresset. “We are committed to rapidly increasing sales of our innovative Field based products in these important markets and to reaching new audiences in medicinal chemistry, in-licensing and safety. Hiring Mike and Rae will help us quickly achieve that objective.”
For further information, please visit www.cresset-group.com
About Cresset Group Ltd
Cresset develops software for calculating and comparing the molecular Field characteristics of chemical compounds. Field technology uses the surface properties of molecules to evaluate their activities and properties, rather than relying on 2D structure similarity, which enables Cresset’s users to find more interesting, novel and relevant results than other methods. Cresset’s Fields provide a smarter, structure independent way of hit-finding, lead switching and lead optimization in drug discovery and other chemistry-based research projects. Cresset’s Field technologies have been successfully applied to a very wide range of target classes, with and without structural information, on over 80 projects for major pharmaceutical and biotechnology companies. www.cresset-group.com
